tiprankstipranks
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Holding ATXS?
Track your performance easily

Astria Therapeutics (ATXS) Income Statement

1,042 Followers

Astria Therapeutics Income Statement

Last quarter (Q3 2024), Astria Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Astria Therapeutics's net income was $-24.53M. See Astria Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 102.20M$ 67.83M$ 53.50M$ 194.98M$ 37.44M$ 27.09M
Operating Income
$ -102.20M$ -83.03M$ -53.50M$ -194.98M$ -37.44M$ -27.09M
Net Non Operating Interest Income Expense
$ 15.93M$ 10.20M$ 1.72M$ 122.00K$ 236.00K$ 845.00K
Other Income Expense
$ 90.00K$ -15.26M$ -55.00K$ 58.00K$ -101.00K$ -50.00K
Pretax Income
$ -86.36M$ -72.89M$ -51.83M$ -194.91M$ -37.30M$ -26.29M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -86.36M$ -72.89M$ -51.83M$ -219.35M$ -37.30M$ -26.29M
Basic EPS
$ -1.86$ -2.42$ -3.55$ -24.58$ -12.18$ -14.10
Diluted EPS
$ -1.86$ -2.42$ -3.55$ -24.58$ -12.18$ -14.10
Basic Average Shares
$ 194.64M$ 30.12M$ 14.62M$ 8.93M$ 3.06M$ 1.87M
Diluted Average Shares
$ 194.64M$ 30.12M$ 14.62M$ 8.93M$ 3.06M$ 1.87M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 102.20M$ 67.83M$ 53.50M$ 194.98M$ 37.44M$ 27.09M
Net Income From Continuing And Discontinued Operation
$ -86.36M$ -72.89M$ -51.83M$ -194.91M$ -37.30M$ -26.29M
Normalized Income
$ -81.95M--$ -153.98M$ -37.30M$ -26.29M
Interest Expense
-----$ 0.00
EBIT
$ -88.87M$ -72.89M$ -53.50M$ -194.91M$ -37.44M$ -27.09M
EBITDA
$ -88.87M$ -72.89M$ -53.50M$ -194.91M$ -37.44M$ -27.09M
Currency in USD

Astria Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis